miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis
Name
nihms178418.pdf
Size
1.74 MB
Format
Adobe PDF
Checksum (MD5)
a1efc1ed1c3eee32148fa4f6063e8adf
Author(s)
Prabhala, Harsha
Mestdagh, Pieter
Muth, Daniel
Teruya-Feldstein, Julie
Westermann, Frank
Speleman, Frank
Vandesompele, Jo
Ma, Li-Jun
Young, Jennifer J
Pan, Elizabeth
Date Issued
February 2010
Journal
Nature Cell Biology
Publisher
Springer Nature
Citation
Ma, Li, Jennifer Young, Harsha Prabhala, Elizabeth Pan, Pieter Mestdagh, Daniel Muth, Julie Teruya-Feldstein, et al. “miR-9, a MYC/MYCN-Activated microRNA, Regulates E-Cadherin and Cancer Metastasis.” Nature Cell Biology (February 21, 2010).
Version
Author's final manuscript
Abstract
MicroRNAs (miRNAs) are increasingly implicated in regulating the malignant progression of cancer. Here we show that miR-9, which is upregulated in breast cancer cells, directly targets CDH1, the E-cadherin-encoding messenger RNA, leading to increased cell motility and invasiveness. miR-9-mediated E-cadherin downregulation results in the activation of β-catenin signalling, which contributes to upregulated expression of the gene encoding vascular endothelial growth factor (VEGF); this leads, in turn, to increased tumour angiogenesis. Overexpression of miR-9 in otherwise non-metastatic breast tumour cells enables these cells to form pulmonary micrometastases in mice. Conversely, inhibiting miR-9 by using a 'miRNA sponge' in highly malignant cells inhibits metastasis formation. Expression of miR-9 is activated by MYC and MYCN, both of which directly bind to the mir-9-3 locus. Significantly, in human cancers, miR-9 levels correlate with MYCN amplification, tumour grade and metastatic status. These findings uncover a regulatory and signalling pathway involving a metastasis-promoting miRNA that is predicted to directly target expression of the key metastasis-suppressing protein E-cadherin.
MIT Department
Broad Institute of MIT and Harvard
Massachusetts Institute of Technology. Department of Biology
Massachusetts Institute of Technology. Division of Comparative Medicine
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/ncb2024
